Skip to main content
. 2024 Aug 27;14(11):4806–4818. doi: 10.1016/j.apsb.2024.08.023

Figure 5.

Figure 5

In vitro and in vivo activities of VNAR-5G8 fused with PE38. (A) Schematic view of 5G8-PE38 construction. (B) Cytotoxicity of 5G8-PE38 in HUVEC cells. (C) Cytotoxicity of 5G8-PE38 in MDA-MB-468 cells. (D) Apoptosis of HUVEC and MDA-MB-468 cells treated with PBS, R1C2-PE38, and 5G8-PE38 for 24 h determined by flow cytometry. (E) Statistical plot of 5G8-PE38 induced apoptosis in HUVEC and MDA-MB-468 cells. (F) Tumor tissues were stripped from mice at the end of treatment. (G) Treatment timeline in mice receiving 5G8-PE38 and relative tumor volumes (n = 6 mice per group). (H) Tumor weight following treatment. (I) Representative immunofluorescence images of MDA-MB-468 tumor sections stained for DAPI (4′,6-diamidino-2-phenylindole) (DAPI, blue), Bcl-2 (green) and Ki-67 (red) proliferation marker (Scale bar = 100 μm). (J) Body weight following treatment (n = 6 mice per group). (K) Liver, spleen, and kidney weights following treatment. (n = 6 mice per group). Data are reported as the mean ± SD, ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001).